Scientists at Columbia University have joined a regional consortium of academic and industry partners to accelerate the development of new drugs that target SARS-CoV-2.
Omicron relatives called BA.4 and BA.5 are behind a fresh wave of COVID-19 in South Africa, and could be signs of a more predictable future for SARS-CoV-2.
